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Summary
Background: Previous studies have suggested that genetic variation in the beta2 (β2-AR) and beta3 (β3-AR)
adrenergic receptor genes are associated with obesity and insulin resistance. The aim of this
study was to evaluate the influence of beta2 (Gln27>Glu) and beta3 (Trp64>Arg) adrenorecep-
tor gene polymorphisms on BMI and carbohydrate-lipid metabolism in Polish obese families.
Material/Methods: 122 persons (84 women, 38 men) from 40 obese families (BMI 33.5±7.7) were included. PCR-
RFLP analysis of genotype was plotted against anthropometric parameters and the results of
glucose and lipid oral tolerance tests. Venous blood samples were analysed for concentrations
of glucose, insulin, free fatty acids, triglycerides, total cholesterol, HDL-chol, LDL-chol, leptin,
and vWF.
Results: We found 39% Glu27 with 8% Arg64 allele frequencies. The blood glucose and insulin concen-
tration during OGTT and blood FFA and TG level during OLTT was lower in patients with
the Glu/Glu β2-AR polymorphism than Glu/Gln and Gln/Gln. In the obese patients the same
effect was observed; however, the percent of fat body mass, leptin concentration, and BMI was
higher in this group. Patients with the Trp/Trp polymorphism in the β3-AR gene were charac-
terized by higher glucose and insulin concentration during OGTT and higher blood concen-
tration of FFA and TG during OLTT. These results were independent of BMI value.
Conclusions: The β2-AR 27Glu and β3-AR 64Arg alleles have a protective effect against metabolic disorders
in obese families from southern Poland.
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BACKGROUND
It is well documented that both environmental and
genetic factors are involved in the onset and progres-
sion of obesity in humans. Severe obesity appears to
have a particularly strong genetic component and is
polygenic in nature [1]. The sympathetic nervous sys-
tem plays a key role in regulating the energy balance
[2]. The adrenergic receptor genes are suggested to be
the ‘candidate genes’ for obesity development, and for
carbohydrate and lipid metabolism disorders.
The beta2 (β2-AR) and beta3 (β3-AR) adrenergic recep-
tors are the main receptors involved in the regulation of
thermogenesis and lipolysis in brown and white adipose
tissue in rodents. Both β2-AR and β3-AR are expressed
in human adipose tissue cells [3]. The beta-adrenergic
receptors bind the endogenous catecholamines, transfer
the signals to the interior of cells via the stimulatory
guanine nucleotide–binding protein (Gs), and regulate
basal metabolic rate (BMR) [4].
A comparison of the primary structures of beta-receptors
confirms their remarkable degree of conservation, par-
ticularly in their transmembrane domains. There are,
however, a number of species-related differences [5].
The structure of these receptors is characterized by the
presence of seven hydrophobic regions, corresponding
presumably to seven transmembrane domains [5]. The
subtypes of beta-receptors appear to have an extracellu-
lar glycated N-terminal domain. In contrast to β1-AR
and β2-AR, the C-terminal intracellular domain of β3-
AR is apparently voided at the third intracellular loop,
which is the phosphorylation target sequence of protein
kinase A or beta adrenergic kinase [6]. Phosphorylation
of β2-AR has been shown to be one of the first steps in
receptor desensitization after agonist binding, thus the
absence of the phosphorylation site may well explain
resistance to short term desensitization [7].
The β3-AR is strikingly different from the β1 and β2-AR
subtypes; it recognizes most of the β1 and β2-AR antag-
onists as agonists [6]. Another difference between β3-
and β1- or β2-AR is that β3-AR reveals a lower affinity
for catecholamines. This suggests that β1- and β2-ARs
mediate the effect of circulating catecholamines, where-
as the β3-AR mediates only the effects of much higher
concentrations of norepinephrine [8].
A distinguishing feature of the β3-AR is that it appears
to be relatively resistant to desensitization and down-
regulation. This leads to the hypothesis that its primary
function may be to maintain signaling during periods of
sustained sympathetic stimulation [9].
Genes encoding the various adrenergic receptor sub-
types may respond to different signals during ontogene-
sis. The majority of β3 specific mRNA is detected in
brown adipose tissue, which in mammals other than
rodents is found mainly in newborns or in pathological
situations, such as pheochromocytoma, or rare climatic
conditions (extreme cold) [6]. Isolated brown or white
adipocytes found throughout the lifespan of human
adults do, however, express β3-AR at the same time as
they express β2- and β1-AR.
In adipocyte-like cells (3T3-F44-2A), the expression of
β2-AR may be considerably up-regulated, and that of
β1- and β3-AR almost completely suppressed by treat-
ment with dexamethasone [5]. This up-regulation of β2-
AR may be explained by the existence in the 5 flanking
region of the β2-AR gene several glucocorticoid respon-
sive elements consensus sequences, which are potential
sites of interaction with the glucocorticoid receptor [5].
The β2-AR gene displays high genetic variability and
common polymorphisms at codon, such as Arg16Gly or
Gln27Glu (point mutation: C→G), and a mutation at
codon 164 (Thr164Ile) could result in altered receptor
function [10]. It has been suggested that the Glu27 vari-
ant is resistant to agonist-promoted down-regulation
[11]. Although this variant has been associated with obe-
sity [12,13] and type 2 diabetes [14,15], the findings have
not been replicated in all studies [16,17]. Other authors
have reported that polymorphisms in the β2-AR gene
may influence the effects of physical activity [18] or diet
[4] in the determination of body fat mass. In addition,
the C to T nucleotide substitution at nucleotide 47 has
been described in the 5’ leader cistron (LC) of the β2-AR
gene (5’LCAArg19-Cys), which is in linkage disequilibri-
um with the codon 16 and 27 polymorphisms [19].
A Trp64 Arg polymorphism in the first intracellular
loop of the β3-AR gene (a non-conservative missense
mutation, T→A) has been described in some studies as
being associated with obesity and a variety of its related
traits, such as high BMI and WHR, increased capacity
to gain weight and decreased energy expenditure,
insulin resistance and an earlier onset of type 2 diabetes
[2,20,21]. These findings have been replicated in several
[1,21–23] but not all studies [24]. The inconsistencies
between studies have led some investigators to conclude
that this polymorphism plays little if any role in human
obesity [7].
The human β2-AR stimulates both lipolysis and fat tis-
sue blood flow [25]. Evidence that β3-AR is expressed in
visceral fat makes it a prime candidate for the regula-
tion of lipolysis and insulin sensitivity in humans [26].
This receptor, by stimulating the uncoupling protein
UCP-1, alters respiration coupling and dissipates oxida-
tion-derived energy as heat [27]. Moreover, β3-AR-
mediated effects are hypothesized to be modulated by
leptin and vice versa [8].
The involvement of β2-AR and β3-AR in metabolic dis-
orders suggests that polymorphism in the encoding
genes might be an inter-individual susceptibility factor
for these disorders and a myriad of disorders connected
with them, i.e. breast cancer [28] and colon cancer [29].
Significantly, studies reported to date underline ethnic
differences that imply region-specific polymorphism
and its interaction with other obesity risk factors; for
instance with polymorphisms of other obesity candidate
genes, such as UCP-1 [10,30–32], D2R [32,33] and the
peroxisome proliferator receptor (PPAR) gamma [34],
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physical inactivity, and a high carbohydrate/fatty diet.
The strong impact of gender on the effects of polymor-
phism has also been proved in several studies [34].
The postulated role of the β2- and β3-ARs polymor-
phisms in obesity and its metabolic consequences
prompted us to investigate the role of the Gln27Glu β2-
AR and Trp64Arg β3-AR gene polymorphisms in mem-
bers of obese families from Southern Poland.
MATERIAL AND METHODS
Our study was performed in 122 patients (38 men and
84 women) who belonged to 40 families with the genetic
trait of obesity. Increased body weight (body mass index
≥30) was detected in at least two generations of the stud-
ied families. The subjects were recruited from outpa-
tients seen at the Clinic of Lipid Disorders and Obesity
in Cracow, Poland. All biochemical estimations were
performed at the Department of Clinical Biochemistry,
Jagiellonian University, Cracow, Poland. Patients with
serious accompanying diseases (diabetes mellitus, can-
cer, inflammatory disease, symptomatic atherosclerosis,
liver damage or any other disorder affecting metabo-
lism) were excluded from the study. For at least two
weeks before the study all patients consumed their usual
diet, did not change their physical activity level, and did
not take any medication that would influence the results
of blood tests for lipids and carbohydrates. None had
undertaken a weight-reducing effort during the most
recent 6 months. All patients gave their informed con-
sent to participate in the study, which was approved by
the Ethics Committee of the Jagiellonian University in
Cracow.
During the initial visit all patients were examined and
office blood pressure was measured three times with a
mercury sphygmomanometer after the patient had been
seated for 10 minutes in a quiet room, according to ISH
guidelines. A minimum of 3 readings were performed,
and the average of the last 2 readings was recorded.
Body mass index (BMI) was calculated with the usual
formula, weight (kg)/height2 (m). The waist was mea-
sured with a soft tape midway between the lowest rib
and the iliac crest, and hip circumference at the widest
part of the glutteal region. The waist-hip-ratio (WHR)
was calculated as a measure of central adiposity. Body
composition was determined by bioelectrical impedance
(Maltron BF-905): percent body fat, measured as a per-
centage of total body weight and free fat mass,
expressed as kilograms of free fat mass.
The laboratory blood tests, oral glucose tolerance test
and oral lipid tolerance test were performed on differ-
ent days. Blood samples were obtained after overnight
fasting for genotyping and for estimation of blood con-
centration of glucose, insulin, total cholesterol (TCh),
HDL, triglycerides (TG), free fatty acids (FFA), leptin,
and von Willebrandt Factor (vWF).
For the oral glucose tolerance test (OGTT), a blood sam-
ple was drawn from a peripheral vein after overnight
fasting, and again after ingestion of 75 g of glucose in a
volume 300 ml every 30 minutes for 120 min. to mea-
sure blood glucose and insulin concentration.
The oral lipid tolerance test (OLTT) was performed
according to Couderc, 1998 [35]. After a standard meal
(energy intake of 1033 kcal, 40% fats (80 g), 20% pro-
teins, 40% carbohydrate), blood samples were obtained
at 2, 4, 6 and 8 hours to measure TG, FFA, leptin and
insulin determination.
Blood glucose was measured by an enzymatic colorimet-
ric method using glucose oxidase (Cormay Diagnostic,
Poland). Total cholesterol, HDL and triglycerides were
measured by an enzymatic method (Cormay Diagnostic,
Poland). FFA concentration was measured by an opti-
mized enzymatic colorimetric assay (Roche Diagnostic,
Mannheim, Germany). Plasma insulin levels were esti-
mated by immuno-radioassay (Polatom, Otwock,
Poland). The serum concentration of leptin was assayed
by radio-immunoassay kits (LINCO). The vWF concen-
tration was determined by a commercial enzyme
immunoassay kit (Diagnostica Stago, France).
Blood vWF estimation was also made in a group of 10
healthy volunteers (5 men, 5 women) aged 48±7.9 years
as a control for the measurements performed in
patients from obese families.
Insulin resistance was evaluated using several indexes:
• HOMA-IR (homeostasis model assessment of insulin
resistance) according to the equation:
HOMA-IR = [Fasting insulin(mikroU/mL)×(fasting
glucose(mmol/l)]/22.5 [36],
• DELTA (early secretory response to an oral glucose
load) according to the equation:
DELTA= [DELTA I30-I0 (pmol/L)] / DELTA G30-G0
(mmol/L)] [37],
• AUC-: the computed area under the curve, expressed
the glucose, insulin, FFA and leptin concentrations
during tests.
Genomic DNA was isolated from whole blood using
QIAamp Blood and Tissue Kits (Qiagen Inc, Germany).
The Trp64Arg β3-AR gene polymorphism was deter-
mined by polymerase chain reaction (PCR) performed
with 20 ng of genomic DNA with upstream primer
5’ CCA GTG GGC TGC CGA GGG 3’ and downstream
primer 5’ GCC AGT GGC GCC CAA CGG 3’. The result-
ing 248 bp product was digested with Mva I (Amersham
Pharmacia Biotech). The digested products were subject-
ed to electrophoresis through a 3% agarose gel. The gel
was stained with ethidium bromide and DNA was visu-
alised by UV transillumination. The presence of two
restriction sites (Trp64 allele) resulted in fragments of 97,
61 and 64 bp, and the loss of one restriction site
(Arg64allele) resulted in fragments of 158 and 64 bp.
The primers that were used to amplify simultaneously
codon 27 for measurement of the Gln27Glu polymor-
phism were derived from the genomic sequence of the
β2-AR gene. The forward primer was 5’ GAA TGA GGC
TTC CGA GCG TC 3’ and the reverse primer was
5’ GGC CCA TGA CCA GAT CGA CA 3’ resulting in a
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353 bp product size. The expected sizes after digestion
with ITA I (Amersham Pharmacia Biotech) were 174,
97, 55 and 27 bp for Gln27 homozygotes; 229, 97 and
27 bp for Glu27 homozygotes; and 229, 174, 97, 55 and
27 bp for heterozygotes.
Statistical analysis
The results of continuous variables are expressed as
means ± SD. Before statistical analysis, normal distribu-
tion and homogeneity of variables were tested. We used
the χ2 test for comparisons of proportions and the
unpaired t test for comparisons of quantitative variables.
The levels of statistical significance were set at p<0.05.
The statistical analysis was performed with the Statistica
for Windows software from Statsoft.
RESULTS
The characteristics of the studied patients are given in
Table1. The females were significantly older than the
males. There was no difference in BMI between the
men and the women, but the WHR ratio was higher in
the men.
The mean value of blood leptin was significantly higher
in the women than in the men.
The whole study group of patients revealed a higher
(but not significantly higher) blood concentration of
vWF (120.9%±43.4) as compared to the 10 healthy vol-
unteers (80.6%±41.2).
The distribution of genotypes was consistent with the
population, in Hardy-Weinberg equilibrium, and not
significantly influenced by gender and obesity status.
The genotype distribution of the β2-AR Gln27Glu poly-
morphism in the whole group was 42%, 40 % and 18%
for the Gln27Gln, Gln27Glu and Glu27Glu genotypes
respectively. The genotype distribution of the β3-AR in
the study group was 86%, 13% and 1% for Trp64Trp,
Trp64Arg and Arg64Arg respectively.
The allele frequency of β2-AR Glu27 was 39%, and β3-
AR Arg64, 8%.
The blood glucose concentration in all patients with the
Glu/Glu β2-AR polymorphism was lower than in
Glu/Gln and Gln/Gln carriers during the entire OGTT
(significantly at 90 min after glucose ingestion) (Figu-
re 1). The serum insulin concentration was also the low-
est in subjects with the Glu/Glu polymorphism, but not
significantly (Figure 2).
In the group of patients with BMI <30 kg/m2 there
were no differences in blood glucose and insulin con-
centration during OGTT among different Glu27 β2-AR
allele carriers. In the obese patients (BMI>30 kg/m2,
the subjects with the Glu/Glu polymorphism revealed a
tendency to lower concentration of glucose and insulin
measured in blood during OGTT, although the percent
of fat body mass and BMI was the highest in this group
(Table 2). In the group of men with Glu/Glu polymor-
phism (n=5), the leptin level was 28.53 ng/ml and was
significantly higher (p<0.001) than in the men with
Gln/Gln (10.19 ng/ml) and Gln/Glu (13.16 ng/ml).
The blood concentrations of TG and FFA measured
during OLTT were the highest in the group of Gln/Gln
β2-AR carriers, while the lowest TG concentrations were
observed in patients with Glu/Glu polymorphism; how-
ever, the differences were not significant (Figure 3,4).
The obese men (BMI≥30 kg/m2) with Gln/Gln polymor-
phism revealed a higher concentration of vWF (p<0.05)
compared to obese carriers of Gln/Glu (Table 2).
The patients with Trp/Trp polymorphism in the β3-AR
gene were characterized by an insignificantly higher
glucose concentration in comparison to Arg carriers
during the whole OGTT (Figure 5).
Age [years]
BMI [kg/m2]
WHR
Lean body mass%
Fat body mass %
Diastolic BP [mmHg]
Systolic BP [mmHg]
vWF [%]
Fasting glucose[mmol/l]
Fasting insulin [µU/ml}
TCh [mmol/l]
HDL [mmol/l]
LDL [mmol/l]
Leptin [pg/ml]
HOMA- IR
DELTA
43.55
33.26
0.87
57.38
37.92
80.7
129.22
120.94
5.50
15.78
5.18
1.34
3.09
22.59
3.95
849.64
19.15
7.67
0.1
11.79
16.9
11.8
14.52
43.42
0.92
9.97
1.21
0.32
1.01
14.69
2.84
5284.64
46.46
33.67
0.84
51.61
36.39
80.29
129.08
119.13
5.51
15.71
5.21
1.39
3.05
27.41
3.97
1153.08
18.44
7.35
0.08
7.98
14.37
10.90
13.36
40.19
0.98
10.23
1.18
0.32
1.08
12.38
3.09
6524.15
37.13
32.36
0.93
68.30
40.81
81.74
129.57
124.35
5.48
15.92
5.13
1.24
3.17
12.57
3.91
272.12
19.36
8.36
0.09
10.01
20.86
14.03
17.45
49.40
0.79
9.61
1.28
0.29
0.82
14.26
2.33
184.29
0.012*
0.383
0.000**
0.000**
0.274
0.622
0.892
0.568
0.890
0.926
0.749
0.017*
0.591
0.000**
0.925
0.455
Whole group (n=122) Female (n=84) Male (n=38)
Aver. SD Aver. SD Aver. SD Male vs. female
p
Table 1. Characteristics of the study group (*p<0,05; **p<0,001).
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Insulin concentration during the whole OGTT was also
higher among patients with Trp/Trp polymorphism
(Figure 6), with statistically significant results at 90 min
into the OGTT.
The group of men with BMI<30 kg/m2 and the
Trp/Trp variant had lower glucose concentration (sig-
nificantly at 60 and 90 min of the OGTT and AUC Glu)
and slightly lower AUC Ins value during OGTT, which
argues for better glucose tolerance (Table 3).
An analysis of the OLTT results shows higher blood
concentration of Tg (Figure 7) and FFA (Figure 8) in
the group of Trp/Trp carriers. The blood concentration
of insulin at 0, 2, 6, and 8 hours into the test was higher
among patients with the Trp/Trp polymorphism
(Figure 9).
DISCUSSION
The results of our study suggest that the Arg64 variant
of β3-AR gene is not frequent in the population of
southern Poland. The second investigated mutation of
Figure 1. Glucose concentration during OGTT in patients with
polymorphism β-2AR.
Figure 3. Tryglicerides concentration during OLTT in patients with
polymorphism β-2AR.
Figure 4. Free facid acid concentration during OLTT in patients with
polymorphism β-2AR.
Figure 5. Glucose concentration during OGTT in patients with
polymorphism β-3AR.
Figure 6. Insulin concentration during OGTT in patients with
polymorphism β-3AR.
Figure 2. Insulin concentration during OGTT in patients with
polymorphism β-2AR.
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the β2-AR gene is more frequent, which points to the
role of ethnic differences in the frequency of the obesity
related ‘gene candidate’ polymorphisms [1,23,25,32].
We found no significant relations between the investi-
gated polymorphisms of AR genes and BMI values;
however, we observed statistically significant links
between these polymorphisms and some metabolic
parameters among the members of obese families.
Focusing on the investigated β3-AR polymorphism, it
should be noted that two of the β3-AR 64 Arg allele car-
riers represented the highest BMI value, approaching
Age [years]
BMI [kg/m2]
WHR
Lean body mass%
Fat body mass %
Diastolic BP [mmHg]
Systolic BP [mmHg]
vWF [%]
O Glucose 0 [mmol/l]
G Glucose 30 [mmol/l]
T Glucose 60 [mmol/l]
T Glucose 90 [mmol/l)]
Glucose 120 [mmol/l]
Insulin 0 [µU/ml]
Insulin 30 [µU/ml]
Insulin 60 [µU/ml]
Insulin 90 [µU/ml]
Insulin 120 [µU/ml]
AUC Glu
AUC Ins
HOMA-IR
DELTA
31.60
23.00
0.82
61.50
18.00
80.00
127.50
123.82
5.17
7.23
6.83
5.83
5.25
7.30
60.84
76.58
46.22
35.14
752.88
6145.80
1.77
191.86
26.82
4.11
0.10
2.12
5.66
14.14
12.58
48.06
0.80
1.66
0.85
0.88
1.03
3.59
41.39
54.69
21.00
12.67
68.41
3098.31
1.08
86.17
30.31
26.08
0.88
56.50
21.75
74.00
124.00
91.32
4.83
7.25
6.88
6.15
4.74
12.00
83.58
93.18
76.20
31.03
751.86
8233.88
2.57
227.01
21.40
0.80
0.04
9.40
3.10
5.48
8.94
27.98
0.39
0.68
2.15
1.57
1.30
6.28
61.79
78.48
35.41
17.73
131.16
5082.68
1.48
174.31
35.71
27.50
0.86
61.00
24.00
70.00
110.00
147.45
5.20
6.86
7.69
6.53
4.55
9.40
82.00
86.20
91.40
24.75
778.43
8300.25
2.14
325.66
24.45
2.12
0.04
0.00
0.00
0.00
0.00
38.54
0.47
0.72
2.26
1.19
1.16
2.83
48.79
17.82
16.40
12.80
106.17
1356.58
0.46
35.67
0.925
0.098
0.184
0.521
0.329
0.407
0.639
0.217
0.415
0.983
0.963
0.698
0.511
0.198
0.529
0.719
0.156
0.696
0.988
0.469
0.378
0.702
0.850
0.184
0.639
0.879
0.546
0.572
0.302
0.557
0.970
0.783
0.457
0.415
0.467
0.500
0.582
0.826
0.044*
0.373
0.710
0.406
0.670
0.098
Male group I (BMI<30)
Ave. SD
OGTT parameter
Ave. SD Ave. SD Gln/Gln vs.Gln/Glu
Gln/Gln vs.
Glu/Glu
Gln/Gln (n=8) Gln/Glu (n=6) Glu/Glu (n=2) p p
Table 2. The phenotypic and metabolic characteristics of study group males during OGTT, grouped according to BMI value and Gln/Glu status
(polymorphism at position 27 in the b2-AR gene); *p<0,05.
Age [years]
BMI [kg/m2]
WHR
Lean body mass%
Fat body mass %
Diastolic BP [mmHg]
Systolic BP [mmHg]
vWF [%]
O Glucose 0 [mmol/l]
G Glucose 30 [mmol/l]
T Glucose 60 [mmol/l]
T Glucose 90 [mmol/l)]
Glucose 120 [mmol/l]
Insulin 0 [µU/ml]
Insulin 30 [µU/ml]
Insulin 60 [µU/ml]
Insulin 90 [µU/ml]
Insulin 120 [µU/ml]
AUC Glu
AUC Ins
HOMA-IR
DELTA
46.52
36.70
0.98
71.25
39.92
83.75
131.25
112.60
5.92
9.16
10.71
9.11
7.70
19.03
111.43
219.92
175.95
117.82
1079.04
17804.25
4.89
208.47
13.98
5.66
0.04
8.09
11.86
11.88
16.42
41.77
0.84
1.50
2.68
2.34
3.13
8.87
53.54
93.82
82.90
97.72
243.11
7228.19
2.24
97.11
38.45
38.50
1.01
72.80
54.60
86.67
136.67
166.00
5.92
9.33
9.31
6.96
5.22
18.13
176.23
204.77
108.25
35.08
934.65
15475.75
4.76
401.30
15.19
4.28
0.08
5.97
10.45
15.28
25.17
63.00
0.54
1.78
2.22
1.50
1.77
4.21
64.72
112.31
44.03
27.56
171.46
4018.16
1.15
238.30
23.13
42.00
0.97
71.67
67.67
95.00
140.00
132.70
4.82
8.15
7.42
5.98
4.78
24.03
121.87
139.93
65.70
123.23
790.50
12034.00
5.13
405.39
9.52
11.14
0.11
16.26
41.06
35.36
42.43
59.52
0.08
2.73
1.61
1.63
1.58
20.84
51.98
63.87
20.27
151.15
192.34
4533.60
4.44
370.48
0.270
0.500
0.365
0.706
0.030*
0.742
0.679
0.041*
0.991
0.844
0.298
0.061
0.095
0.821
0.047*
0.775
0.085
0.064
0.225
0.484
0.898
0.000*
0.017*
0.239
0.785
0.948
0.046*
0.420
0.620
0.495
0.000*
0.395
0.072
0.053
0.151
0.525
0.769
0.200
0.046*
0.940
0.089
0.225
0.896
0.110
Male group II (BMI≥30)
Ave. SD
OGTT parameter
Ave. SD Ave. SD Gln/Gln vs.Gln/Glu
Gln/Gln vs.
Glu/Glu
Gln/Gln (n=13) Gln/Glu (n=6) Glu/Glu (n=3) p p
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40 kg/m2 in our group. Regardless of the obesity phe-
notype, the mutated allele carriers presented with
physiological lipid parameters (high HDL, low FFA),
good lipid tolerance during OLTT, as well as good glu-
cose tolerance parameters. Statistically their levels of
insulin and the insulin resistance index (ISI-HOMA)
were significantly decreased, pointing to good insulin
sensitivity.
Thomas et al. in 1999 [12] suggested the possibility of
coexistence of the Trp64Arg β3-AR polymorphism and
a form of visceral obesity with decreased lipolysis. The
Age [years]
BMI [kg/m2]
WHR
Lean body mass%
Fat body mass %
Diastolic BP [mmHg]
Systolic BP [mmHg]
vWF [%]
O Glucose 0 [mmol/l]
G Glucose 30 [mmol/l]
T Glucose 60 [mmol/l]
T Glucose 90 [mmol/l)]
Glucose 120 [mmol/l]
Insulin 0 [µU/ml]
Insulin 30 [µU/ml]
Insulin 60 [µU/ml]
Insulin 90 [µU/ml]
Insulin 120 [µU/ml]
AUC Glu
AUC Ins
HOMA-IR
DELTA
ISI-Comp
25.44
24.39
0.85
59.83
20.83
77.50
122.50
119.51
4.93
6.85
6.60
5.94
4.86
9.62
71.91
78.19
66.73
30.16
728.64
7101.67
2.11
248.48
6.06
16.77
3.55
0.07
6.97
4.22
10.35
11.65
40.44
0.42
0.65
1.20
0.89
0.90
5.04
45.12
53.28
33.34
14.13
67.51
3747.82
1.14
118.37
3.69
74.96
27.00
0.93
51.00
22.00
70.00
130.00
89.90
5.55
8.78
9.00
6.75
5.22
8.35
77.65
112.15
59.05
38.95
897.08
8175.00
2.19
141.18
4.65
4.29
0.00
0.00
0.00
0.00
0.00
0.00
60.81
1.25
1.89
2.27
2.63
2.42
4.60
75.45
82.38
21.57
13.51
107.87
3954.14
1.60
129.57
2.50
0.001*
0.331
0.270
0.293
0.808
0.356
0.409
0.386
0.185
0.016*
0.044*
0.400
0.691
0.752
0.885
0.467
0.767
0.444
0.013*
0.724
0.939
0.281
0.627
Trp/Trp (n=14)
OGTT parameter
X/Arg (n=2) p
Male group I (BMI<30)
Ave. SD Ave. SD Trp/Trp vs. Trp/Arg
Table 3. The phenotypic and metabolic characteristics of study group males during OGTT, grouped according to BMI value and Trp/Arg
(polymorphism at position 64 in the b3-AR gene); *p<0,05.
Age [years]
BMI [kg/m2]
WHR
Lean body mass%
Fat body mass %
Diastolic BP [mmHg]
Systolic BP [mmHg]
vWF [%]
O Glucose 0 [mmol/l]
G Glucose 30 [mmol/l]
T Glucose 60 [mmol/l]
T Glucose 90 [mmol/l)]
Glucose 120 [mmol/l]
Insulin 0 [µU/ml]
Insulin 30 [µU/ml]
Insulin 60 [µU/ml]
Insulin 90 [µU/ml]
Insulin 120 [µU/ml]
AUC Glu
AUC Ins
HOMA-IR
DELTA
ISI-Comp
40.16
38.29
0.99
72.32
48.74
85.83
135.00
128.45
5.72
9.08
9.75
8.00
6.48
20.01
136.31
202.51
141.79
95.97
987.88
16157.84
5.00
303.04
2.04
15.23
6.04
0.06
8.35
19.93
16.21
21.11
54.14
0.79
1.77
2.59
2.40
2.91
9.79
60.56
95.82
79.33
97.99
232.13
6114.52
2.26
213.42
0.82
61.41
30.00
0.99
60.00
29.00
90.00
120.00
160.40
6.44
8.64
7.97
7.19
10.00
58.90
87.90
52.80
2.86
159.48
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.188
0.195
0.936
0.168
0.347
0.810
0.509
0.571
0.384
0.810
0.991
0.816
0.332
0.229
0.516
0.673
0.370
0.520
Trp/Trp (n=21)
OGTT parameter
X/Arg (n=1) p
Male group II (BMI≥30)
Ave. SD Ave. SD Trp/Trp vs. Trp/Arg
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mutated allele has also been associated with impaired
catecholamine-induced lipolysis in other studies
[38–40]. The mechanism by which this may influence
FFA and other parameters of glucose/fat metabolism is
still not clear. A lower FFA concentration seems to pro-
tect against consequences leading to metabolic disor-
ders. As postulated, FFA stimulates hepatic glucose and
lipoproteins production [41,42] and interferes with
insulin extraction [43]. By substrate competition in the
muscle, higher FFA concentrations can lead to impaired
insulin-stimulated glucose metabolism and insulin resis-
tance. In the pancreas, increased FFA concentrations
induce beta-cell dysfunction. In our group of patients,
the low level of FFA may be related to low activity of
lipolysis in mutated β3-AR allele carriers. This mutation
may, in this way, be responsible for relatively normal
glucose tolerance in spite of obesity in our group.
Several reports [44–46] have failed to replicate in
humans the original reports indicating an association
between the Arg64 allele in β3-AR and weight gain,
insulin resistance and diabetes [43,47,48]. One potential
reason for discrepancies among investigators is that this
genetic variant may interact with the other genetic vari-
ants (polymorphisms) influencing body fat [49].
A thrifty gene haplotype is an hypothesis also worth
mentioning. The β3-AR 64Arg allele seems to be a
thrifty gene candidate as it is more frequent among the
women and is associated with menarche at earlier age,
and with a decrease in energy expenditure [40].
When the results for mutated β-3AR Glu27 carriers are
analyzed, it is evident that there exists a higher frequen-
cy of this allele among the non-obese women (BMI<30)
in our group. Homozygotic carriers of this allele with
BMI>30 were characterized by lower glucose and
insulin level during the OGTT test, as well as low TG
level during the OLTT test, pointing to the low fre-
quency of metabolic, or at least carbohydrate catabolic
complications.
Evidence for the role of β2-AR in the etiology of obesity
has been explored in recent studies. This mutation has
been reported to be associated with obesity in Japanese
men and women [13,14]. Swedish women homozygous
for Glu27 had an average fat mass in excess of twenty kg
and approximately 50% larger fat cells than women
homozygous for Gln27. There have been no significant
associations observed concerning changes in β2-AR
function, as assessed by in vitro fat cell lipolysis experi-
ments [12].
Statistically, in our study non-obese men with BMI <30
had a significantly lower level of FFA and increased
level of leptin. The hypothesis which emerges from our
results is that the lipolysis may be more efficient in β2-
AR Glu27 carriers than in Gln27 carriers, leading to
changes in lipolytic parameters. As efforts to analyze the
activity of Glu27 isoform indicate, it does not reach the
mature wild type conformation. This may result in an
altered ability to be degraded, with metabolic conse-
quences [10].
In another stratification, the subgroup of obese men
(BMI>25) carrying this mutation was characterized by
lower glucose, insulin, LDL and TG levels. However,
the men in this group were younger in comparison to
non-carriers of the mutation. The results may be due to
the differences in age, since aging is known to reduce
the adrenergic receptor beta sensitivity [50,51].
Our results are in line with a Swedish study [35], in
which obesity in males tended to be negatively associat-
ed with the β2-AR 27Glu mutation. The genetic factors
contributing to obesity are different between men and
Figure 7. Tryglicerides concentration during OLTT in patients with
polymorphism β-3AR.
Figure 8. Tryglicerides concentration during OLTT in patients with
polymorphism β-3AR.
Figure 9. Free fatty concentration during OLTT in patients with
polymorphism β-3AR.
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women. Moreover, it has been shown that in Japanese
subjects the frequency of the β2-AR Glu27allele in obese
was higher than in non-obese subjects [13,14]. However,
the frequency of the Glu27 allele in non-obese Japanese
for both genders was much lower compared with that
found in French or Swedish subjects. This difference
may partially explain the differences in metabolic rates
observed between Japanese and European subjects [18].
It has also been shown that physical activity, another
compensation mechanism of lipid and glucose tolerance,
was able to counterbalance the effect of β2-AR Gln27Glu
polymorphism to increase body weight, body fat and obe-
sity in men [18]. However, since we did not test the physi-
cal activity of our subjects, we cannot address this issue.
Depending on group stratification according to BMI
value (we used cut-off values of 25 or 30), the obesity
results were significantly different; thus supporting the
well-known influence of obesity per se on metabolic
parameters.
The introduced stratification related to blood pressure
value revealed statistically significant higher insulin level
among men-carriers of β2-AR 27Gln in comparison to
non-carriers of this allele. As there were no more signifi-
cant associations, this is unlikely to implt any linkage of
the examined polymorphisms and susceptibility to
hypertension. This issue has also been studied in other
populations [51].
CONCLUSIONS
We found that the presence of polymorphisms of the
β2- and β3-AR genes in our population is not directly
related to obesity. Our results even revealed the protec-
tive effect of β2-AR 27Glu and β3-AR 64Arg alleles on
metabolic (lipid and glucose tolerance) parameters in
obese families of Southern Poland.
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